Elacestrant

艾拉司群

Report date: 2026/05/23 20:00:57
NME

Base Information

Drug NameElacestrant
Drug Alias Nameelacestrantum依拉司群OrserduER-306323RAD-1901
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEstrogen receptor alpha antagonists
TargetsEstrogen receptor alpha
Therapy Area/IndicationsVasomotor symptomMetastatic breast cancerHot Flashes +[16] 
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/01/27
Country/TerritoryCzechiaBelgiumBulgaria +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesEisai Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteTranslational Breast Cancer Research ConsortiumSciclone Pharmaceuticals（China）Co Ltd +[12] 
Inactive CompaniesContext Therapeutics IncYale UniversityRadius Pharmaceuticals, Inc +[4] 
Active IndicationsMetastatic breast cancerBrain DiseasesCentral Nervous System Diseases +[12] 
Inactive IndicationsVasomotor symptomHot FlashesBreast Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG